A systematic review and meta-analysis of efficacy and safety of Calcimimetic agents in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease

CONCLUSION: Calcimimetic agents can reduce the PTH level, Ca level, P level, calcium-phosphorus product level and do not increase the serious adverse events.PMID:36305135 | DOI:10.2174/1381612829666221027110656

Source: Current Pharmaceutical Design - October 28, 2022 Category: Drugs & Pharmacology Authors: Yiping Liu Qian Yang Guangyong Chen Tianbiao Zhou Source Type: research